Complete Genomics focuses on human genome sequencing. It uses a proprietary method to support drug discovery and development and clinical use of sequencing information. The company just raised $45 million in a Series D financing. (Press Release) That is a lot of money at a time when it has been difficult for emerging firms to find venture capital or private equity funding. Many biotech businesses have liquidated or substantially scaled back. The investment is an indication that some of the nation’s most sophisticated investors still believe that good returns can be made in the genomics business and that personalized medicine will become prevalent. The biotech drugs which are developed using genetic information and the clinical services which utilize individualized genomic profiles are expensive. The continuing growth of this sector will be one factor potentially pushing health care costs higher in the next decade.
About this Blog
The Healthy Skeptic is a website about the health care system, and is written by Kevin Roche, who has many years of experience working in the health industry. Mr. Roche is available to assist health care companies through consulting arrangements through Roche Consulting, LLC and may be reached at [email protected].
Healthy Skeptic Podcast
Subscribe to Blog via Email
Amwell, a telehealth company which went public recently, is following the well-trod path to try to convince investors it has a business which justifies the valuation by buying two other...
July 28, 2021